In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.

The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.

The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in comprehending the evolving treatment landscape, including understanding trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions will focus on emerging approved therapies and investigational agents, with an intent to provide insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the skills to navigate the latest oncology research and clinical care confidently.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: GSK, Merck, AbbVie, AstraZeneca, Corcept Therapeutics, Verastem, Eisai, Natera, Karyopharm Therapeutics, BioNTech

The GOG Foundation, Inc. would also like to thank our sponsors for this symposium: Gilead, Faeth Therapeutics